Stellar Biotechnologies Inc  

(Public, CVE:KLH)   Watch this stock  
Find more results for cve:klh
0.0000
- Close
CVE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 3.88 - 14.33
Open     -
Vol / Avg. 0.00/5,576.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.44
Shares 8.45M
Beta     -
Inst. own     -
Dec 12, 2016
Q4 2016 Stellar Biotechnologies Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 13, 2016
Stellar Biotechnologies Inc at Rodman & Renshaw Global Investment Conference
Aug 10, 2016
Q3 2016 Stellar Biotechnologies Inc Earnings Call
Aug 9, 2016
Q3 2016 Stellar Biotechnologies Inc Earnings Release
  

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -333.87% -374.73%
Operating margin -267.81% -571.85%
EBITD margin - -550.83%
Return on average assets -63.04% -22.87%
Return on average equity -74.13% -36.20%
Employees 23 -
CDP Score - -

Address

332 E Scott St
PORT HUENEME, CA 93041-2939
United States - Map
+1-805-4882800 (Phone)
+1-805-4882889 (Fax)

Website links

Description

Stellar Biotechnologies, Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades, formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer, immune disorders, Alzheimer's disease and inflammatory diseases, or it can be used as a finished, injectable product in the immunodiagnostic market for measuring immune response in patients and research settings.